Procaps Group and Genomma Lab Internacional, S.A.B. de C.V. announced a strategic agreement to develop, manufacture and market five Softgel products within Latin America. Through this partnership, Procaps will manufacture and Genomma will market and distribute the products.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.727 USD | -0.83% | +0.63% | -33.00% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
16.3 MXN | +3.16% | +8.23% | 882M | ||
2.727 USD | -0.83% | +0.63% | 308M | ||
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-33.00% | 308M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- PROC Stock
- News Procaps Group S.A.
- Procaps Group and Genomma Lab Announce Strategic Agreement to Manufacture and Market Softgel Products in Latin America